Merck’s targeted lung cancer drug tepotinib wins early access in UKThe UK drugs regulator has backed Merck KGaA’s MET inhibitor for the treatment of some patients with non-small Share XMerck’s targeted lung cancer drug tepotinib wins early access in UKhttps://pharmaphorum.com/news/mercks-targeted-lung-cancer-drug-tepotinib-wins-early-access-in-uk/
MHRA grants bluebird ‘innovation passport’ for sickle cell therapybluebird bio’s sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an ‘innovation passport’ introduced Share XMHRA grants bluebird ‘innovation passport’ for sickle cell therapyhttps://pharmaphorum.com/news/mhra-grants-bluebird-innovation-passport-for-sickle-cell-therapy/
Janssen COVID jab cleared in UK as fears of third wave mountWith concern already growing about a possible third wave of COVID-19 infections, the UK has cleared the use Share XJanssen COVID jab cleared in UK as fears of third wave mounthttps://pharmaphorum.com/news/janssen-covid-jab-cleared-in-uk-as-fears-of-third-wave-mount/
UK will offer under-30s alternative to AZ’s COVID jabThe UK drugs regulator has said people aged under 30 should be offered an alternative to the AstraZeneca Share XUK will offer under-30s alternative to AZ’s COVID jabhttps://pharmaphorum.com/news/uk-will-offer-under-30s-alternative-to-azs-covid-jab/
Paediatric trial of AZ COVID jab ‘halted as a precaution’Oxford University has suspended a clinical trial of its AstraZeneca-partnered COVID-19 vaccine in children and adolescents while a Share XPaediatric trial of AZ COVID jab ‘halted as a precaution’https://pharmaphorum.com/news/paediatric-trial-of-az-covid-jab-halted-as-a-precaution/
MHRA launches patient involvement pilot for drug applicationsThe UK drugs regulator is now asking that all applications for new medicines or indications detail the efforts Share XMHRA launches patient involvement pilot for drug applicationshttps://pharmaphorum.com/news/mhra-launches-patient-centric-pilot-for-drug-applications/
Novavax confirms efficacy of COVID-19 jab against UK variantA clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, Share XNovavax confirms efficacy of COVID-19 jab against UK varianthttps://pharmaphorum.com/news/novavax-confirms-efficacy-of-covid-19-jab-against-uk-variant/
New era of genomic medicine begins as UK approves Lilly’s RetsevmoThe UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung Share XNew era of genomic medicine begins as UK approves Lilly’s Retsevmohttps://pharmaphorum.com/news/uk-authorises-lillys-ret-targeted-retsevmo/
MHRA approves Seagen’s oral HER2 drug TukysaThe UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after Share XMHRA approves Seagen’s oral HER2 drug Tukysahttps://pharmaphorum.com/news/mhra-approves-seagens-oral-her2-drug-tukysa/
